Allarity Therapeutics, Inc. 8-K

What Happened Allarity Therapeutics, Inc. filed an 8-K (Item 3.02) disclosing an additional closing of a previously announced private placement. On December 23, 2025, the company issued and sold 255,103 shares of common stock at $0.98 per share (the Nasdaq Rule 5635(d) minimum price), generating gross proceeds of approximately $250,000. The private placement originally began under a Securities Purchase Agreement dated September 22, 2025, under which the company sold 1,562,500 shares and/or pre‑funded warrants for about $2.5 million.

Key Details

• Additional closing date: December 23, 2025 (subject to customary closing conditions).
• Shares issued at $0.98 per share, the minimum price under Nasdaq Rule 5635(d).
• Additional shares issued: 255,103; gross proceeds from this tranche: ~ $250,000.
• Earlier tranche (Sept. 22, 2025) raised ~ $2.5 million via sale of 1,562,500 shares and/or pre‑funded warrants.

Why It Matters This filing notifies investors of a completed unregistered securities sale that modestly increases Allarity’s cash resources. The company stated it intends to use net proceeds for general corporate purposes and working capital. Investors should note the shares were sold in a private placement at the Nasdaq minimum price and that the transaction was not a public offering.